Alembic Pharmaceuticals’ Partner NATCO Receives USFDA Tentative Approval for Olaparib Tablets

What Happened ?

key details

USFDA Tentative Approval for Olaparib Tablets:

• USFDA Tentative Approval: NATCO Pharma Limited received tentative approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Olaparib Tablets, 100 mg and 150 mg. 
• Reference Product: The approved ANDA is therapeutically equivalent to Lynparza® (Olaparib) Tablets, 100 mg and 150 mg, marketed by AstraZeneca Pharmaceuticals LP, for the indications specified in the approved labeling. 
• Commercial Partnership: Under the collaboration, NATCO Pharma will manufacture the Olaparib tablets, while Alembic Pharmaceuticals will exclusively distribute the product in the United States once all regulatory and legal requirements are satisfied. 
• Large Addressable Market: According to IQVIA, the reference product recorded an estimated U.S. market size of approximately USD 1.4 billion for the twelve months ended March 2026, highlighting the commercial potential of the product. 
• Patent Litigation Status: The company stated that the Paragraph IV (Para IV) patent litigation relating to the product remains ongoing. The tentative approval does not permit immediate commercial launch until applicable legal and regulatory conditions are fulfilled. 
• Strengthening U.S. Portfolio: The approval further expands Alembic’s presence in the U.S. generic pharmaceutical market through its strategic manufacturing and commercialization partnership with NATCO Pharma. 
• Regulatory Track Record: Following this development, Alembic Pharmaceuticals has accumulated 244 USFDA ANDA approvals, comprising:
  • 224 Final Approvals
  • 20 Tentative Approvals

Note:

• The tentative approval represents an important regulatory milestone for Alembic Pharmaceuticals’ U.S. business.
• While commercialization remains subject to the outcome of the ongoing Paragraph IV litigation and fulfillment of regulatory requirements, the approval provides access to a product targeting a sizeable U.S. oncology market and reinforces the company’s long-term strategy of expanding its U.S. generics portfolio through strategic partnerships.

Risk Analysis

Summary:

• Alembic Pharmaceuticals’ announcement represents a positive regulatory milestone for its U.S. generics business. However, the approval is tentative and does not authorize immediate commercialization. The timing of the product launch remains dependent on the resolution of the ongoing Paragraph IV patent litigation and satisfaction of applicable regulatory requirements.

Key Risks:

• Patent Litigation Risk: The Paragraph IV litigation relating to Olaparib Tablets is ongoing and could affect the timing or ability to commercially launch the product in the U.S. 
• Regulatory Risk: Tentative approval is not equivalent to final approval. Commercial distribution can commence only after all regulatory conditions are met. 
• Commercial Execution Risk: Successful commercialization will depend on coordinated execution between NATCO Pharma, as the manufacturer, and Alembic Pharmaceuticals, as the U.S. distributor. 
• Competitive Market Risk: The product will compete in the U.S. oncology generics market, where pricing dynamics, additional generic entrants, and market exclusivity periods may influence commercial performance.

Worst Case:

• If the ongoing patent litigation results in an unfavorable outcome or regulatory approvals are delayed, the commercial launch of Olaparib Tablets could be postponed or prevented, limiting Alembic’s ability to participate in the estimated U.S. market opportunity.

Risk Level: Medium

Company Commentary

• Alembic Pharmaceuticals informed the stock exchanges that its partner NATCO Pharma Limited has received USFDA Tentative Approval for Olaparib Tablets, 100 mg and 150 mg. 
• The approved ANDA is therapeutically equivalent to Lynparza® Tablets of AstraZeneca Pharmaceuticals LPfor the approved indications. 
• NATCO Pharma will manufacture the product, while Alembic Pharmaceuticals will distribute it in the United States upon meeting all legal and regulatory requirements. 
• The company confirmed that the Paragraph IV patent litigation remains ongoing, and the approval is currently tentative. 
• Alembic stated that it now holds a cumulative 244 USFDA ANDA approvals, including 224 final approvals and 20 tentative approvals, reflecting its continued expansion in regulated markets.